Blood screening is a laboratory testing process of extracting blood earlier to its transfusion. This test is carried out for ensuring that recipients get secure blood products. There are several procedures for blood screening of donated blood for ensuring that the safety of blood units. Samples of blood collected through blood donations go through laboratory screenings for Transfusion-Transmissible Infections (TTIs). Blood sample is analyzed for presence of pathogens of some infectious diseases including hepatitis C and B viruses along with human immunodeficiency virus (HIV). Various assay types are used for the blood screening, including nucleic acid amplification technology (NAT) assays and Immunoassays (IAs). Immunoassays (IAs) are further subdivided into categories such as enzyme immunoassays (EIAs), haemagglutination (HA)/particle agglutination (PA) assays, chemiluminescent immunoassays (CLIAs), along with rapid/simple single-use assays (rapid tests).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2409
Global Blood Screening Market- Dynamics
Increasing preference for NAT test over ELISA (enzyme-linked immunosorbent assay), owing to high specificity and sensitivity of viral nucleic acid is expected to propel the global blood screening market growth, during the forecast period. For instance, Grifols, in 2018, received the U.S. Food & Drug Administration (FDA) approval for two assays of blood screening – Procleix WNV and Procleix Ultrio Elite. Both assays operate on completely automated platform for NAT blood screening: Procleix Panther system. With these assays the Procleix Panther system supports blood centers in efficient screening of infectious diseases along with eliminating necessity of batch processing.
Rising blood donation campaigns by NGOs, blood donor agencies, and governments, are expected to drive the global blood screening market growth during the forecast period. For instance, as per the June 2017 data reported by the WHO reported, blood donations of over 112.5 Mn were conducted worldwide and around 50% of this is collected from developed countries, accounting for 19% of global population. Furthermore, increase in government initiatives for creating awareness in people regarding the donated blood safety is expected to propel the global blood screening market growth during the forecast period. For instance, World Health Organization (WHO), in 2014, recommended establishment of a national blood system consisting well-coordinated and organized services for blood transfusion, effective ethical and evidence-based national blood policies, along with regulation and legislation that could provide timely and sufficient supplies of safe blood products and blood to meet the requirements of transfusion for all patients.
However, lack of trained staff along with poor systems quality result in inefficiency of screening systems, inadequate identification procedures, and samples of donor blood and patient misidentification or are amongst the factors restraining the global blood screening market growth.
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2409
Global Blood Screening Market- Regional Analysis
Based on region, the global blood screening market is segregated into North America, Europe, Latin America, Asia Pacific, Africa, and Middle East.
Among regions, North America is expected to hold a dominant position in the global blood screening market, due to acquisitions from key players within this region. For Instance, Grifols, in July 2017, acquired the donor screening unit NAT (Nucleic Acid Testing) by Hologic, a U.S.-based company, for around US$ 1,850 Mn purchase price. The agreement was bound to development, research, manufacture of instruments and assays activities with the help of NAT technology which enables detecting infectious agents from plasma and blood donations, thereby contributing in greater safety of transfusion.
Asia Pacific is expected to witness notable growth within the global blood screening market owing to rising government initiatives along with increasing awareness for diseases transmission during the blood transfusion. For instance, a National Blood Donor Vigilance Programme (NBDVP) was launched, in June 2015, in India on the occasion of World Blood Donor Day. The NBDVP’s objective is increasing the frequency of blood donation and reducing the incidence of adverse events along with analyzing the risk factors and evaluating preventive measures.
Global Blood Screening Market: Competitive Landscape
Major player functioning in the global blood screening market are Grifols, Abbott Laboratories, F. Hoffmann-La Roche, Biomérieux, Siemens Healthineers (A Subsidiary of Siemens AG), Bio-Rad Laboratories, Inc., Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Dickinson and Company, and Beckman Coulter (A Subsidiary of Danaher Corporation) and Becton.
- Abbott Laboratories, in July 2019, received approval from the U.S. Food and Drug Administration (FDA) for its latest plasma and blood screening Alinity s System. The system is designed for screening plasma and blood more efficiently within less space, and even generates the results in reduced time and least human error.
- LifeCell International Pvt. Ltd, in 2018, launched an integrated screening based on DNA – RightStart to diagnose over 50 clinical conditions in newborns.
- Clinical Genomics Pty Ltd, in 2017, introduced blood-based circulating tumor DNA (ctDNA) test to detect colorectal cancer.
- Grifols, S.A and Hologic, Inc., in 2016, in an partnership agreement, got the approval from the US Food and Drug Administration (FDA) for its blood screening assay Procleix Zika virus.
- Hoffmann-La Roche Ltd, in 2016, received approval from the US Food and Drug Administration (FDA) for the cobas MPX test useful with analyzers such as cobas 8800 and 6800 Systems to detect HIV-2, HIV-1, HCV and HBV.
Global Blood Screening Market: Taxonomy
Based on Technology:
- Nucleic acid amplification technology (NAT)
- Immunoassays (IAs)
- Western Blotting
- Next-Generation Sequencing (NGS)
Based on Product Type:
- Reagents & Kits
Based on End User:
- Diagnostics Laboratory
- Blood Banks
Based on Region:
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027